Pharming Group N.V.
PHGUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $297 | $245 | $206 | $190 |
| % Growth | 21.1% | 19.3% | 8.3% | – |
| Cost of Goods Sold | $35 | $25 | $18 | $20 |
| Gross Profit | $240 | $220 | $187 | $170 |
| % Margin | 80.7% | 89.7% | 90.9% | 89.4% |
| R&D Expenses | $83 | $69 | $53 | $67 |
| G&A Expenses | $92 | $81 | $62 | $35 |
| SG&A Expenses | $99 | $88 | $69 | $92 |
| Sales & Mktg Exp. | $7 | $7 | $6 | $57 |
| Other Operating Expenses | $61 | $69 | $48 | -$3 |
| Operating Expenses | $243 | $225 | $170 | $157 |
| Operating Income | -$4 | -$5 | $18 | $28 |
| % Margin | -1.2% | -2.2% | 8.9% | 14.7% |
| Other Income/Exp. Net | $0 | -$7 | -$3 | -$5 |
| Pre-Tax Income | -$8 | -$12 | $15 | $22 |
| Tax Expense | $3 | -$1 | $1 | $7 |
| Net Income | -$11 | -$11 | $14 | $16 |
| % Margin | -3.8% | -4.4% | 6.7% | 8.4% |
| EPS | -0.017 | -0.015 | 0.021 | 0.025 |
| % Growth | -12.7% | -171.4% | -16% | – |
| EPS Diluted | -0.017 | -0.015 | 0.019 | 0.023 |
| Weighted Avg Shares Out | 688 | 675 | 651 | 696 |
| Weighted Avg Shares Out Dil | 688 | 675 | 720 | 701 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $4 | $0 | $0 |
| Interest Expense | $10 | $6 | $6 | $6 |
| Depreciation & Amortization | $11 | $16 | $13 | $20 |
| EBITDA | $14 | $10 | $34 | $49 |
| % Margin | 4.6% | 4% | 16.3% | 25.7% |